Adiponectin and visfatin concentrations in children treated with valproic acid

Epilepsia

Volumn 49, Issue 2, 2008, Pages 353-357

  Rauchenzauner, Markus ^a   Haberlandt, Edda ^a   Scholl Bürgi, Sabine ^a   Ernst, Barbara ^a   Hoppichler, Fritz ^b   Karall, Daniela ^a   Ebenbichler, Christoph F ^a   Rostasy, Kevin ^a   Luef, Gerhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Special Institute for Preventive Cardiology and Nutrition   (Austria)

Author keywords

Adiponectin; Children; Visfatin; VPA; Weight

Indexed keywords

ADIPONECTIN; ETIRACETAM; INSULIN; LAMOTRIGINE; LEPTIN; OXCARBAZEPINE; SULTIAME; VALPROIC ACID; VISFATIN;

ADOLESCENT; ADULT; ARTICLE; BODY COMPOSITION; CHILD; CONTROLLED STUDY; EPILEPSY; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC REGULATION; OBESITY; PRIORITY JOURNAL;

ADIPONECTIN; ADIPOSE TISSUE; AGE FACTORS; ANTICONVULSANTS; BLOOD GLUCOSE; CHILD; EPILEPSY; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; VALPROIC ACID; WEIGHT GAIN;

EID: 38649139906     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01460.x     Document Type: Article

References (19)

1. Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE 2003) Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol 18 : 133 139.
2. Biton V 2006) Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agent. Neurologist 12 : 163 167.
3. Chandran M, Phillips SA, Ciaraldi T, Henry RR 2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26 : 2442 2450.
4. Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, Lai MM, Lin CC 2007) The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56 : 1216 1220.
5. Commission on Classification and Terminology of the International League Against Epilepsy 1989) Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30 : 389 399.
6. Davis R, Peters DH, McTavish D 1994) Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47 : 332 372.
7. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S 1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36 : 54 59.
8. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I 2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 : 426 430.
9. Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A 2005) Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 65 : 1808 1809.
10. Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, Kapiotis S, Wolzt M 2006) The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 43 : 548 549.
11. Korner A, Kratzsch J, Gausche R, Schaab M, Erbs S, Kiess W 2007) New predictors of the metabolic syndrome in children - role of adipocytokines. Pediatr Res 61 : 640 645.
12. Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Gneiß H, Hesse V, von Hippel A, Jaeger U, Johnsen D, Korte W, Menner K, Mueller G, Mueller J, Niemann-Pilatus A, Remer T, Schaefer F, Wittchen H, Zabransky S, Zellner K, Ziegler A, Hebebrand J 2001) Perzentilen für den body-mass-index für das kindes- und jugendalter unter heranziehung verschiedener deutscher stichproben. Monatsschrift Kinderheilkunde 149 : 807 818.
13. Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, Bauer G, Lechleitner M 2004) Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 55 : 729 732.
14. Matsuzawa Y 2006) The metabolic syndrome and adipocytokines. FEBS Lett 580 : 2917 2921.
15. Pecoraro P, Guida B, Caroli M, Trio R, Falconi C, Principato S, Pietrobelli A 2003) Body mass index and skinfold thickness versus bioimpedance analysis: fat mass prediction in children. Acta Diabetol 40 (Suppl 1 S278 S281.
16. Pylvanen V, Pakarinen A, Knip M, Isojarvi J 2006) Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 8 : 643 648.
17. Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA 2002) Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 87 : 4652 4656.
18. Tilg H, Moschen AR 2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6 : 772 783.
19. Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, Kotani K, Kameda-Takemuara K, Tokunaga K, Matsuzawa Y 1996) Insulin resistance and body fat distribution. Diabetes Care 19 : 287 291.